ASCO 2021 | Predictions for thyroid cancer in the next 10 years

Marcia Brose, MD, PhD, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, shares exciting progress being made in the thyroid cancer space. Significant scientific advances in the molecular characterization of thyroid cancer have enabled the identification of more targetable mutations and the development of novel targeted agents. Continued growth of the treatment armamentarium is expected over the coming years, with hopes that new investigational agents will show clinically relevant benefits for patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.